NCT07217119 · OUTCOME
DE Phase: Plasma Concentration of Belantamab Mafodotin Antibody-Drug Conjugate (ADC) Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM · Source last updated 2026-06-25
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure MEAN
Unit Nanogram/ millilitre (ng/mL)
Interval / dispersion Standard Deviation
Time frame Predose, end of infusion (EOI), 2 and 24 hours postdose on Cycle (C) 1 Day (D) 1; anytime sample at C1 D4 and D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at end of treatment (EoT, up to approximately 281 weeks.) What was measured Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.
Analysis population: Pharmacokinetic (PK) population included all participants in the safety population from whom at least one PK sample has been obtained and analysed. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.
Groups in this outcome 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 9 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Reported measurements C1 D1, PRE-DOSE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 9 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 9 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 5
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0.0 0.00 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 0.0 0.00 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0.0 0.00 Not reported Not reported Not reported
C1 D1, END OF INFUSION Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 9 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 30088.9 7793.18 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 43460.0 7254.76 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 48350.0 15195.76 Not reported Not reported Not reported
C1 D1, 2 HOURS Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 9 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 29933.3 5308.95 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 41370.0 10445.10 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 40600.0 8739.34 Not reported Not reported Not reported
C1 D1, 24 HOURS Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 9 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 19100.0 4184.20 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 28350.0 9022.35 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 33383.3 10192.43 Not reported Not reported Not reported
C1 D4, ANYTIME SAMPLE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 8 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10310.0 4016.24 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 14512.0 6392.34 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 22783.3 7980.33 Not reported Not reported Not reported
C1 D8, ANYTIME SAMPLE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 8 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 10 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 5325.0 1740.97 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 6828.0 3273.79 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 13208.3 7262.77 Not reported Not reported Not reported
C2 D1, PRE-DOSE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 8 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 8 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1885.0 755.32 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1806.3 859.18 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3774.8 2319.76 Not reported Not reported Not reported
C2 D1, END OF INFUSION Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 8 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 8 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 31062.5 3108.48 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 40525.0 12523.32 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 39195.0 20443.90 Not reported Not reported Not reported
C4 D1, PRE-DOSE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 4 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2720.0 1129.07 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3395.0 1578.05 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 4235.3 3102.85 Not reported Not reported Not reported
C4 D1, END OF INFUSION Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 4 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 32533.3 6459.36 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 56550.0 21043.21 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 46766.7 12470.90 Not reported Not reported Not reported
C6 D1, PRE-DOSE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2700.0 452.55 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2933.3 2578.16 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3983.3 1228.59 Not reported Not reported Not reported
C6 D1, END OF INFUSION Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 28400.0 3818.38 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 48800.0 8660.83 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 40366.7 3550.12 Not reported Not reported Not reported
C9 D1, PRE-DOSE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 2
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3895.0 148.49 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 4453.3 1170.70 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3385.0 1053.59 Not reported Not reported Not reported
C9 D1, END OF INFUSION Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 2
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 28250.0 5868.99 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 34166.7 5832.10 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 47050.0 16899.85 Not reported Not reported Not reported
C12 D1, PRE-DOSE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1587.0 1432.60 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3580.0 5062.88 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 2230.0 NA Not reported Not reported SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
C12 D1, END OF INFUSION Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 2 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 1
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 25600.0 8485.28 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 39600.0 424.26 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 28200.0 NA Not reported Not reported SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
C18 D1, PRE-DOSE Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 0
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1450.0 NA Not reported Not reported SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant. 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 6300.0 NA Not reported Not reported SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
EoT (up to ~ 281 weeks) Analysis denominator · Participants
Group Source count 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 4 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 5 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation Group Value Spread Lower Upper Comment 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 3755.0 2353.23 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab 1779.8 1830.77 Not reported Not reported Not reported 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab 4576.7 4803.09 Not reported Not reported Not reported
Complete source fields classes categories measurements
group Id OG000
spread 0.00
value 0.0
group Id OG001
spread 0.00
value 0.0
group Id OG002
spread 0.00
value 0.0 denoms counts
group Id OG000
value 9
group Id OG001
value 9
group Id OG002
value 5
units Participants
title C1 D1, PRE-DOSE categories measurements
group Id OG000
spread 7793.18
value 30088.9
group Id OG001
spread 7254.76
value 43460.0
group Id OG002
spread 15195.76
value 48350.0 denoms counts
group Id OG000
value 9
group Id OG001
value 10
group Id OG002
value 6
units Participants
title C1 D1, END OF INFUSION categories measurements
group Id OG000
spread 5308.95
value 29933.3
group Id OG001
spread 10445.10
value 41370.0
group Id OG002
spread 8739.34
value 40600.0 denoms counts
group Id OG000
value 9
group Id OG001
value 10
group Id OG002
value 6
units Participants
title C1 D1, 2 HOURS categories measurements
group Id OG000
spread 4184.20
value 19100.0
group Id OG001
spread 9022.35
value 28350.0
group Id OG002
spread 10192.43
value 33383.3 denoms counts
group Id OG000
value 9
group Id OG001
value 10
group Id OG002
value 6
units Participants
title C1 D1, 24 HOURS categories measurements
group Id OG000
spread 4016.24
value 10310.0
group Id OG001
spread 6392.34
value 14512.0
group Id OG002
spread 7980.33
value 22783.3 denoms counts
group Id OG000
value 8
group Id OG001
value 10
group Id OG002
value 6
units Participants
title C1 D4, ANYTIME SAMPLE categories measurements
group Id OG000
spread 1740.97
value 5325.0
group Id OG001
spread 3273.79
value 6828.0
group Id OG002
spread 7262.77
value 13208.3 denoms counts
group Id OG000
value 8
group Id OG001
value 10
group Id OG002
value 6
units Participants
title C1 D8, ANYTIME SAMPLE categories measurements
group Id OG000
spread 755.32
value 1885.0
group Id OG001
spread 859.18
value 1806.3
group Id OG002
spread 2319.76
value 3774.8 denoms counts
group Id OG000
value 8
group Id OG001
value 8
group Id OG002
value 6
units Participants
title C2 D1, PRE-DOSE categories measurements
group Id OG000
spread 3108.48
value 31062.5
group Id OG001
spread 12523.32
value 40525.0
group Id OG002
spread 20443.90
value 39195.0 denoms counts
group Id OG000
value 8
group Id OG001
value 8
group Id OG002
value 6
units Participants
title C2 D1, END OF INFUSION categories measurements
group Id OG000
spread 1129.07
value 2720.0
group Id OG001
spread 1578.05
value 3395.0
group Id OG002
spread 3102.85
value 4235.3 denoms counts
group Id OG000
value 3
group Id OG001
value 4
group Id OG002
value 3
units Participants
title C4 D1, PRE-DOSE categories measurements
group Id OG000
spread 6459.36
value 32533.3
group Id OG001
spread 21043.21
value 56550.0
group Id OG002
spread 12470.90
value 46766.7 denoms counts
group Id OG000
value 3
group Id OG001
value 4
group Id OG002
value 3
units Participants
title C4 D1, END OF INFUSION categories measurements
group Id OG000
spread 452.55
value 2700.0
group Id OG001
spread 2578.16
value 2933.3
group Id OG002
spread 1228.59
value 3983.3 denoms counts
group Id OG000
value 2
group Id OG001
value 3
group Id OG002
value 3
units Participants
title C6 D1, PRE-DOSE categories measurements
group Id OG000
spread 3818.38
value 28400.0
group Id OG001
spread 8660.83
value 48800.0
group Id OG002
spread 3550.12
value 40366.7 denoms counts
group Id OG000
value 2
group Id OG001
value 3
group Id OG002
value 3
units Participants
title C6 D1, END OF INFUSION Show more (12 of 18) denoms counts
group Id OG000
value 9
group Id OG001
value 10
group Id OG002
value 6
units Participants
description Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.
dispersion Type Standard Deviation groups
description Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
id OG000
title 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
description Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
id OG001
title 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
description Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
id OG002
title 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab
param Type MEAN
population Description Pharmacokinetic (PK) population included all participants in the safety population from whom at least one PK sample has been obtained and analysed. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.
reporting Status POSTED
time Frame Predose, end of infusion (EOI), 2 and 24 hours postdose on Cycle (C) 1 Day (D) 1; anytime sample at C1 D4 and D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at end of treatment (EoT, up to approximately 281 weeks.)
title DE Phase: Plasma Concentration of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)
type SECONDARY
unit Of Measure Nanogram/ millilitre (ng/mL) Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle